Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2002

View Archived Issues

Sangamo awarded grant to apply ZFP technology to treatment of sickle cell disease

Bayer Diagnostics to acquire Visible Genetics

G17DT receives orphan drug status in gastric cancer

Inhibition of amyloid fibrillation as a target for therapeutic intervention in AD4

Improving CNS drainage using COGNIShunt system may slow progression of AD

New formulation of Rapamune introduced in U.K.

GLI-5021: a novel therapeutic for acute and chronic myocardial ischemia

KRN-4884 mimics effects of hypoxic preconditioning in coronary preparations

PST-2744 tested in cardiomyopathic hamster model of heart failure

PPARgamma ligand protects heart from reperfusion injury

MCH1 receptor validated as promising target for Rx of obesity, depression and anxiety at Synaptic

Phase I/II results for VB2-011 encouraging

Aromatase inhibitor from Yamanouchi withdrawn from development

Access initiates OraDisc phase III trial, acquires rights to amlexanox

University of Kentucky researchers present morphine derivatives with analgesic activity

Oral formulation of YM-087 dropped from development

Novel bradykinin antagonists identified at Pfizer

Texas Biotechnology presents novel alpha4beta1 integrin antagonists

Daiichi discontinues development of nefiracetam in further territories

Novel antibacterial compounds isolated from Actinomadura sp. cultures

Integrin antagonists and their use in allergic rhinitis and other disorders

Merck describes basic research in the area of tyrosine kinase inhibitors

Thrombin receptor antagonists designed at Merck

FDA approves Zelnorm for IBS in women with constipation

Seattle Genetics provides second-quarter update

Regeneron initiates phase II testing of IL-1 Trap in rheumatoid arthritis